Literature DB >> 9950072

Induction of hepatic mrp2 (cmrp/cmoat) gene expression in nonhuman primates treated with rifampicin or tamoxifen.

H M Kauffmann1, D Keppler, T W Gant, D Schrenk.   

Abstract

The multidrug resistance protein 2 (Mrp2) also called canalicular multidrug resistance protein (cMrp) or canalicular multispecific organic anion transporter (cMoat) is a transmembrane export pump located at the canalicular domain of hepatocytes. Mrp2 transports a broad spectrum of organic anions including glucuronides, glutathione conjugates, and organic sulphates into bile. Based on previous observations in rat hepatocytes, the inducibility of mrp2 gene expression in primate liver was investigated in rhesus monkeys treated with tamoxifen or rifampicin. It was found that treatment with tamoxifen (25 mg/kg per day; over 7 days) or rifampicin (15 mg/kg per day; over 7 days) leading to an induction of cytochrome P450 3A4, resulted in a strong increase in mrp2 mRNA in the liver of male and female rhesus monkeys. On the protein level, tamoxifen also was a highly effective inducer, while rifampicin showed some inducing effect in a female and was inactive in a male monkey. In sections of paraffin-embedded liver tissue, immunofluorescence staining confirmed the results of Western blot analysis. Induced Mrp2 was localized to the canalicular domain of the hepatocytes. In conclusion, our data show inducibility of mrp2 gene expression in the liver of primates which may represent an adaptive response aimed at the enhanced biliary elimination of the inducing drugs and/or their metabolites.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9950072     DOI: 10.1007/s002040050571

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  7 in total

1.  Cytochrome P450 mRNA expression in peripheral blood lymphocytes as a predictor of enzyme induction.

Authors:  Curtis E Haas; Daniel Brazeau; Denise Cloen; Brent M Booker; Valerie Frerichs; Colleen Zaranek; Reginald F Frye; Thomas Kufel
Journal:  Eur J Clin Pharmacol       Date:  2005-07-22       Impact factor: 2.953

Review 2.  Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.

Authors:  Tessa M Bosch; Irma Meijerman; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 3.  Regulation of hepatic ABCC transporters by xenobiotics and in disease states.

Authors:  Xinsheng Gu; Jose E Manautou
Journal:  Drug Metab Rev       Date:  2010-08       Impact factor: 4.518

4.  The effect of rifampin treatment on intestinal expression of human MRP transporters.

Authors:  M F Fromm; H M Kauffmann; P Fritz; O Burk; H K Kroemer; R W Warzok; M Eichelbaum; W Siegmund; D Schrenk
Journal:  Am J Pathol       Date:  2000-11       Impact factor: 4.307

Review 5.  The apical conjugate efflux pump ABCC2 (MRP2).

Authors:  Anne T Nies; Dietrich Keppler
Journal:  Pflugers Arch       Date:  2006-07-18       Impact factor: 3.657

Review 6.  ABC of oral bioavailability: transporters as gatekeepers in the gut.

Authors:  C G Dietrich; A Geier; R P J Oude Elferink
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

7.  Basolateral and canalicular transport of xenobiotics in the hepatocyte: A review.

Authors:  G J Diaz
Journal:  Cytotechnology       Date:  2000-11       Impact factor: 2.058

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.